Pivotal readout

BrightGene's BGM0504 meets goals in two Chinese phase 3 type 2 diabetes trials

Across two phase 3 studies in 780 Chinese adults, the GLP-1/GIP agonist BGM0504 hit its primary and key secondary endpoints. After 32 weeks, 10 mg lowered HbA1c by 2.6 points against 0.51 on placebo, and by 2.41 against 1.95 with semaglutide. BrightGene plans a diabetes filing in China, where it already has an obesity application pending.

Written by Gosset from public sources. Source types: SEC/exchange filing. Sources are available to Gosset users. Log in to see them.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call